Small molecule regulators of alveolar type 2 cell proliferation for the treatment of pulmonary diseases
AssigneeThe Scripps Research Institute
InventorsMichael J. Bollong, Peter G. Schultz, Sida Shao, Arnab Chatterjee, Jian Jeffrey Chen, Nan Zhang
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to compounds. and to their pharmaceutical compositions. that inhibit dipeptidyl peptidase IV (DPP4). Hie compounds selectively promote the proliferation of alveolar type 2 cells (AEC2s) and are useful in therapeutic methods of treating diseases whose etiology, for example, derives from epithelial degeneration and maladaptive remodeling, such as pulmonary' diseases like idiopathic pulmonary fibrosis (IFF), acute respiratory' distress syndrome (ARDS), and infant respiratory' distress syndromes (IRDS).
Claims12
A method of selectively increasing the proliferation of cuboidal alveolar type 2 (AEC2) cells or restoring diminished proliferation of AEC2 cells, which comprises administering to a subject in need thereof an effective amount of a dipeptidyl peptidase-4(DPP4) inhibitor.
Dependencies are inferred from the claim text.